Description: Korro Bio, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, OPERA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson's disease, Amyotrophic lateral sclerosis, severe alcohol-associated hepatitis, and other subsets of pain. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S for the discovery and development of new genetic medicines to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.
Home Page: www.korrobio.com
One Kendall Square
Cambridge,
MA
02139
United States
Phone:
617 468 1999
Officers
| Name | Title |
|---|---|
| Mr. Nessan Bermingham Ph.D. | Co-Founder & Independent Chairman of the Board |
| Mr. Ram Aiyar MBA, Ph.D. | CEO, President & Director |
| Dr. Jean-Francois Formela M.D., MBA | Co-Founder & Independent Director |
| Mr. Vineet Agarwal M.B.A. | Chief Financial Officer |
| Mr. Andrew Fraley Ph.D. | Co-Founder & Advisor |
| Dr. Joshua Rosenthal Ph.D. | Co-Founder & Advisor |
| Mr. Todd Chappell M.B.A. | Chief Operating Officer |
| Mr. Jeffrey M. Cerio J.D., Pharm.D. | Senior VP & General Counsel |
| Ms. Stephanie Engels | Senior VP and Head of People & Culture |
| Mr. Marco A. Passini Ph.D. | VP & Head of CNS biology |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.2926 |
| Price-to-Sales TTM: | 0 |
| IPO Date: | 2023-11-06 |
| Fiscal Year End: | December |
| Full Time Employees: | 101 |